English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Breast and prostate cancers are among the most common of all cancers. They are referred to as hormone‐dependent cancers, because estrogen and androgen are involved in their development and growth. The effects of these hormones are mediated by their respective receptors, estrogen receptor ( ER ) α and androgen receptor. Around 18 years ago, a second  ER ,  ER β, which has a very similar structure to  ER α, was discovered. Its function has been investigated using a variety of methods and biological systems, leading to our present understanding that  ER β can interact with or inhibit  ER α and androgen receptor function directly and/or indirectly, suppress cell growth, and influence responsiveness to endocrine therapy. In order to apply the “inhibition of cell growth” function to cancer treatment, several specific  ER β agonists have been synthesized and are being tested for effectiveness in cancer treatment. We need to keep our eyes on  ER β.

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects